VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ICLRICON Public Limited Company
$169.86$13.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksICLRFinancials

ICON Public Limited Company (ICLR) Financials

28Y historyFree accessUpdated daily

Gross margins have experienced structural erosion, contracting from 30.0% in 2023Q4 to 23.5% in 2026Q1 due to persistent labor inflation and service delivery costs.

ICLR Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05May'05May'04May'03May'02May'01May'00May'99
Sales/Revenue8.25B8.28B8.12B7.74B5.48B2.8B2.81B2.6B1.76B1.67B1.57B1.5B1.34B1.12B945.73M900.04M887.61M865.25M630.72M455.6M346.2M326.66M296.92M225.72M156.56M116.16M80.77M55.8M
Revenue Growth %-0.37%1.99%4.89%41.24%95.93%-0.3%8.09%47.62%5.52%5.81%4.77%12.52%19.83%17.9%5.08%1.4%2.58%37.18%38.44%31.6%5.98%10.01%31.54%44.18%34.77%43.82%44.74%-
Cost of Goods Sold6.08B5.85B5.72B5.53B3.97B1.99B1.97B1.83B1.03B961.33M908.98M903.17M845.41M718.13M611.92M541.39M507.78M489.24M354.48M256.26M220.02M162.56M162.56M122.37M83.37M63.8M42.04M29.3M
COGS % of Revenue73.63%70.58%70.44%71.4%72.48%71.11%70.36%70.36%58.66%57.69%57.71%60.08%63.28%64.41%64.7%60.15%57.21%56.54%56.2%56.25%63.55%49.77%54.75%54.21%53.25%54.92%52.06%52.51%
Gross Profit2.18B2.44B2.4B2.21B1.51B808.03M831.7M769.49M726.96M705.15M666M600.15M490.64M396.87M333.81M358.66M379.83M376.01M276.24M199.33M126.18M134.36M134.36M103.35M73.18M52.36M38.72M26.5M
Gross Margin %26.37%29.42%29.56%28.6%27.52%28.89%29.64%29.64%41.34%42.31%42.29%39.92%36.72%35.59%35.3%39.85%42.79%43.46%43.8%43.75%36.45%41.13%45.25%45.79%46.75%45.08%47.94%47.49%
Gross Profit Growth %-10.7%1.51%8.39%46.82%86.65%-2.85%8.09%5.85%3.09%5.88%10.97%22.32%23.63%18.89%-6.93%-5.57%1.02%36.12%38.58%57.98%-6.09%0%30%41.22%39.76%35.22%46.12%-
Operating Expenses1.16B1.34B1.44B1.42B1.13B416.06M398.3M392.37M392.79M393.46M384.46M397.8M369.48M329.24M294.55M266.56M272.38M276.51M207M151.52M106.37M99.98M99.98M78.42M54.97M41.29M30.57M20M
OpEx % of Revenue14.1%16.16%17.78%18.33%20.61%14.87%14.2%15.12%22.34%23.61%24.41%26.46%27.65%29.53%31.14%29.62%30.69%31.96%32.82%33.26%30.73%30.61%33.67%34.74%35.11%35.54%37.86%35.84%
Selling, General & Admin780.14M728.35M776.36M778.75M585.33M341.69M336.75M325.79M323.74M325.73M326.79M336.46M313.93M280.78M255.86M232.69M230.91M248.78M187.99M136.57M088.81M88.81M71.12M48.95M36.31M27.35M18M
SG&A % of Revenue9.45%8.79%9.56%10.06%10.68%12.21%12%12.55%18.41%19.55%20.75%22.38%23.5%25.18%27.05%25.85%26.01%28.75%29.81%29.98%-27.19%29.91%31.51%31.27%31.26%33.86%32.26%
Research & Development0000000000000000000000000000
R&D % of Revenue----------------------------
Other Operating Expenses383M610.2M667.72M640.35M544.36M74.38M61.55M66.58M69.05M67.73M57.68M61.34M55.55M48.46M38.68M33.87M41.47M27.73M19.01M14.95M106.37M11.17M11.17M7.3M6.02M4.97M3.23M2M
Operating Income1.01B1.1B956.15M795.24M378.53M391.5M433.41M373.36M338.34M311.69M281.54M202.35M121.17M72.42M39.26M92.09M107.45M99.5M69.24M47.82M19.8M18.61M34.38M24.93M18.21M11.08M8.15M6.98M
Operating Margin %12.27%13.26%11.77%10.27%6.91%14%15.45%14.38%19.24%18.7%17.88%13.46%9.07%6.5%4.15%10.23%12.11%11.5%10.98%10.5%5.72%5.7%11.58%11.04%11.63%9.53%10.09%12.51%
Operating Income Growth %-7.77%14.82%20.23%110.09%-3.31%-9.67%16.08%10.35%8.55%10.71%39.13%67%67.31%84.47%-57.37%-14.29%7.99%43.7%44.81%141.45%6.43%-45.88%37.92%36.87%64.44%35.94%16.75%-
EBITDA1.4B1.59B1.54B1.41B738.86M486.11M525.33M439.27M399.59M371.27M339.21M254.89M167.68M115.25M77.94M125.97M140.11M127.23M88.13M62.65M33.68M31.74M45.55M32.2M24.19M16.04M11.38M9.01M
EBITDA Margin %16.91%19.15%18.99%18.21%13.48%17.38%18.72%16.92%22.72%22.28%21.54%16.96%12.55%10.34%8.24%14%15.79%14.7%13.97%13.75%9.73%9.72%15.34%14.26%15.45%13.81%14.08%16.14%
EBITDA Growth %-12.03%2.87%9.37%90.83%51.99%-7.47%19.59%9.93%7.63%9.45%33.08%52.01%45.5%47.86%-38.13%-10.09%10.12%44.36%40.67%86.02%6.11%-30.33%41.48%33.12%50.8%41%26.29%-
D&A (Non-Cash Add-back)383M488.5M585.95M614.73M360.33M94.61M91.92M65.92M61.25M59.58M57.68M52.54M46.51M42.82M38.68M33.87M32.66M27.73M18.89M14.84M13.88M13.13M11.17M7.27M5.97M4.96M3.23M2.03M
EBIT440.57M1.08B935.49M797.58M379.1M394.22M440.26M378.12M340.68M319.85M281.54M211.15M122.15M68.27M30.64M93.86M108.2M102.39M69.24M47.82M14.2M18.61M34.38M24.93M18.21M11.08M8.15M6.98M
Net Interest Income-181M-228.63M-331.69M-227.39M-181.85M-10.29M-6.42M-8.74M-10.28M-11.52M-2.69M366K-302K-796K-448K629K-2.78M-1.22M2.74M3.64M2.18M0288K00000
Interest Income7.11M8.61M5.01M2.35M574K2.72M6.86M4.76M2.35M1.48M1.31M1.15M986K1.15M1.19M1.76M752K2.88M4.14M3.77M2.22M0490K00000
Interest Expense188.11M237.24M336.7M229.73M182.42M13.02M13.28M13.5M12.63M13.01M3.99M785K1.29M1.95M1.64M1.13M3.53M4.11M1.4M125K37.71K281K202K000575K0
Other Income/Expense-759.99M-228.63M-331.69M-230.52M-184.01M-10.66M-6.42M-8.74M-10.28M-11.52M-2.69M366K-302K-5.2M-10.27M629K-2.78M-1.22M2.74M3.64M2.18M979K288K354K1.12M2.52M1.04M2.63M
Pretax Income252.47M869.18M624.08M564.72M194.52M380.84M426.99M368.38M327.67M300.17M278.85M202.72M120.86M67.22M29M92.72M104.67M98.28M71.98M51.46M21.98M19.59M34.67M25.28M19.33M13.6M9.19M9.61M
Pretax Margin %3.06%10.5%7.69%7.29%3.55%13.61%15.22%14.19%18.63%18.01%17.71%13.48%9.05%6.03%3.07%10.3%11.79%11.36%11.41%11.29%6.35%6%11.68%11.2%12.35%11.7%11.38%17.22%
Income Tax23.13M77.71M11.75M59.41M41.33M47.88M51.13M45.56M46.57M37.99M39.31M30.25M18.05M11.8M6.12M5.65M10.38M19.97M15.83M12.92M9.25M5.85M8.93M7M5.13M2.62M3.12M1.56M
Effective Tax Rate %9.16%8.94%1.88%10.52%21.25%12.57%11.98%12.37%14.21%12.66%14.1%14.92%14.94%17.56%21.09%6.1%9.91%20.32%21.99%25.12%42.08%29.88%25.75%27.69%26.54%19.25%33.97%16.2%
Net Income229.34M791.47M612.34M505.3M153.19M327.81M373.99M322.82M281.49M262.18M239.54M172.47M102.81M55.42M22.88M87.07M94.3M78.12M55.96M38.3M12.72M13.54M25.74M18.28M14.2M10.98M6.07M8.05M
Net Margin %2.78%9.56%7.54%6.53%2.79%11.72%13.33%12.44%16.01%15.73%15.21%11.47%7.7%4.97%2.42%9.67%10.62%9.03%8.87%8.41%3.67%4.15%8.67%8.1%9.07%9.45%7.51%14.43%
Net Income Growth %-71.02%29.26%21.18%229.87%-53.27%-12.35%15.85%14.68%7.36%9.45%38.89%67.75%85.51%142.22%-73.72%-7.66%20.71%39.59%46.1%201.21%-6.12%-47.38%40.8%28.75%29.35%80.92%-24.65%-
Net Income (Continuing)229.34M791.47M612.34M505.3M153.19M332.96M375.86M322.66M281.49M262.18M239.54M172.47M102.81M55.42M22.88M87.07M94.3M78.31M55.96M38.53M12.73M13.54M25.74M18.28M14.2M10.98M6.07M8.05M
Discontinued Operations0000000000000000000000000000
Minority Interest0000000000000000001.31M1.12M894K884K000120K00
EPS (Diluted)2.909.537.406.132.256.246.795.905.134.653.972.731.650.920.371.441.571.301.881.330.220.961.881.501.160.920.270.68
EPS Growth %-69.57%28.78%20.72%172.44%-63.94%-8.1%15.08%15.01%10.32%17.13%45.42%65.45%79.35%148.65%-74.31%-8.28%20.77%-30.85%41.35%504.55%-77.08%-48.94%25.33%29.31%26.09%240.74%-60.29%-
EPS (Basic)2.929.607.466.202.286.296.855.965.204.754.082.801.690.920.381.461.611.341.951.350.230.981.941.551.220.970.270.36
Diluted Shares Outstanding78.97M83.03M82.72M82.47M68.07M53.28M54.33M54.74M54.87M56.41M60.29M63.13M62.25M60.68M61.07M60.64M59.9M60.22M29.75M28.86M28.37M13.7M13.7M12.18M12.24M11.94M22.88M11.92M
Basic Shares Outstanding78.42M82.48M82.1M81.53M67.11M52.86M53.86M54.12M54.13M55.25M58.75M61.5M60.91M59.97M60.38M59.72M58.64M58.25M28.71M28.31M28.05M13.27M13.27M11.81M11.66M11.29M22.17M21.01M
Dividend Payout Ratio----------------------------

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Margin compression from labor

Revenue Stagnation Amid Market Headwinds

According to the provided quarterly data, ICON's revenue growth has decelerated significantly, shifting from 5.7% in 2024Q1 to a 1.6% increase by 2026Q1, suggesting that the company is struggling to maintain momentum in a tightening clinical research environment for its core biotechnology client base.

The transition from mid-single-digit growth to near-flat performance indicates that the company's backlog conversion may be facing friction. Investors should monitor whether this trend reflects a broader cooling in R&D spending or specific challenges in executing complex Phase III trials.

Structural Erosion of Gross Profitability

As reported in the financial statements, ICON's gross margin has experienced a notable contraction, falling from 30.0% in 2023Q4 to 23.5% in 2026Q1, which highlights the increasing difficulty in managing pass-through costs and labor inflation within the current clinical trial service delivery model.

This margin compression suggests that the company's pricing power may be limited by competitive pressures or an unfavorable shift in project mix. The inability to maintain gross margins above 25% in recent quarters warrants further investigation into the sustainability of their current cost-plus pricing structure.

Operating Leverage Under Significant Pressure

Based on the reported figures, ICON's operating margin has declined from 14.6% in 2024Q4 to 8.5% in 2026Q1, demonstrating a failure to achieve meaningful operating leverage as SG&A expenses remain sticky despite the lack of top-line expansion across the most recent fiscal periods.

The divergence between revenue stagnation and rising overhead costs suggests that the company is currently unable to scale its infrastructure efficiently. This trend may indicate that the integration of recent acquisitions is proving more resource-intensive than initially anticipated by the market.

Earnings Volatility and Compensation Impact

Analysis of the income statement reveals that net income has become increasingly volatile, with EPS dropping from $3.16 in 2024Q4 to $1.36 in 2026Q1, partly influenced by fluctuating stock-based compensation expenses that reached $89.7 million in 2025Q4, distorting the underlying profitability of the firm.

The significant gap between operating income and net income suggests that non-operating items, including potential interest expenses or integration-related charges, are weighing heavily on the bottom line. Investors should be cautious of relying on headline EPS figures without adjusting for these recurring non-cash and one-time costs.

Sustainability of the Backlog Narrative

While management emphasizes the strength of the contract backlog, the recent stagnation in revenue growth suggests that the market may be overestimating the quality of these commitments, as evidenced by the potential for shadow cancellations in a high-interest rate environment for biotech clients.

Short-term performance metrics indicate that the backlog may not be as resilient as historical trends suggest, particularly if client funding constraints lead to project deferrals. The current valuation appears to assume a level of execution certainty that the recent income statement data does not fully support.

ICLR — Frequently Asked Questions

Quick answers to the most common questions about buying ICLR stock.

What was ICON Public Limited Company's (ICLR) revenue in 2025?

For fiscal year 2025, ICON Public Limited Company (ICLR) reported total revenue of $8.25B. This represents a 14687.3% increase compared to $55.8M in 1998.

Is ICON Public Limited Company (ICLR) profitable?

ICON Public Limited Company (ICLR) is profitable, generating $229.3M in net income for the fiscal year ending 2025 with a net profit margin of 2.8%.

What is ICON Public Limited Company's operating profit margin?

ICON Public Limited Company (ICLR) reported an operating income of $1.01B, resulting in an operating profit margin of 12.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is ICON Public Limited Company's gross profit and gross margin?

ICON Public Limited Company (ICLR) generated $2.18B in gross profit for the year, representing a gross profit margin of 26.4%. This demonstrates the company's core pricing power and production efficiency.